Type 1 Diabetes
NICHE, our subcutaneously implantable platform, is designed to implant insulin-producing cells into the body and provide a locally immuno-protected environment that supports their extended survival.
Precision delivery changes everything
Continuity Biosciences is built on a simple idea: Therapeutic potential should be amplified through precision delivery. By combining advanced engineering with deep biological insights, we develop adaptive delivery platforms that guide promising therapies, from small molecules to biologics and cell-based treatments, exactly where they are needed. Merging medtech and biotech to achieve what neither can alone.
Reach out to explore how our delivery technology works.
Multiple platforms, one purpose:
Delivering treatment precisely where it matters most.
Pancreatic Cancer
Our implantable iontophoretic system uses mild electrical current to deliver chemotherapy directly into tumor tissue, maximizing impact at the source while minimizing systemic exposure.
HIV
Our NanoDDI is a small subdermal implant that delivers sustained therapy over months or years, reducing daily treatment burden and supporting long-lasting effects.
Oral Cavity Cancer
Our iontophoretic system delivers chemotherapy directly into oral tumors using mild electrical current during a brief and minimally invasive outpatient procedure.
Breast Cancer
NDES, our nanofluidic drug-eluting seed, releases therapy directly within the tumor, maintaining a sustained, localized therapeutic presence.
MEDICAL AESTHETICS
Our patch technology goes beyond surface-level aesthetics, using intradermal precision to deliver ingredients beneath the surface for a more targeted approach to skincare.
AND MORE
We are dedicated to solving the delivery challenges that stand between promising therapies and the patients who need them—and we're only getting started.
In the News
Continuity Biosciences and Breakthrough T1D Collaborate to Advance Implantable Cell Therapy Technology Toward First-in-Human Trials
This strategic investment will accelerate development of NICHE, our 3D-printed implantable platform advancing precision delivery for Type 1 diabetes. Designed to implant insulin-producing cells into the body, NICHE creates a protected, vascularized environment that supports their survival and function while reducing the need for whole-body immune suppression.
